^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Antioxidant

    Related drugs:
    2d
    A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS (clinicaltrials.gov)
    P2, N=25, Completed, Lumosa Therapeutics Co., Ltd. | Unknown status --> Completed | Phase classification: P2a --> P2
    Trial completion • Phase classification
    2d
    A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (clinicaltrials.gov)
    P1, N=65, Completed, Lumosa Therapeutics Co., Ltd. | Recruiting --> Completed
    Trial completion
    7d
    The Intervention of Psychobiotics in Patients With Anxiety Disorders (clinicaltrials.gov)
    P=N/A, N=71, Completed, Mackay Memorial Hospital | Recruiting --> Completed | N=120 --> 71
    Trial completion • Enrollment change
    8d
    CaCo: CArotenoid in hypoChOlesterolemia (clinicaltrials.gov)
    P=N/A, N=10, Completed, Hospices Civils de Lyon | Recruiting --> Completed | N=40 --> 10
    Trial completion • Enrollment change
    16d
    A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease (clinicaltrials.gov)
    P2, N=180, Recruiting, Shanghai Auzone Biological Technology Co., Ltd.
    New P2 trial
    17d
    A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Ruijin Hospital | Recruiting --> Active, not recruiting | N=142 --> 28
    Enrollment closed • Enrollment change
    18d
    PROMISE: Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, University of Iowa
    New trial
    26d
    Microbiome and metabolomics analyses of the effect of heat-sensitive moxibustion on allergic rhinitis in rats. (PubMed, Front Immunol)
    Untargeted metabolomics results showed that HM treatment regulated the metabolites such as 1-methylhistidine, xi-3-hydroxy-5-phenylpentanoic acid O-beta-d-glucopyranoside, cladosporin, cuminaldehyde, daidzein, Pe(18:0/15:0), N-nervonoyl asparagine, edulitine, N-arachidonoyl glycine, 9alpha-(3-methyl-2E-pentenoyloxy)-4S-hydroxy-10(14)-oplopen-3-one, quisqualic acid, ethyl glucuronide, zileuton O-glucuronide, trichloroethanol glucuronide, Asp Leu Ser Glu, quinolinic acid, and norvaline...To our knowledge, this represents the first investigation to establish comprehensive correlations between gut microbiota and urinary metabolomics profiles in an AR model. Our findings confirm the therapeutic role of heat-sensitive moxibustion in AR recovery and provide mechanistic insights supporting its clinical application, thereby proposing a novel strategic approach for AR treatment.
    Preclinical • Journal • Metabolomic study
    |
    IL4 (Interleukin 4)
    28d
    MAVEN: MitoQ to Improve Vascular Funciton in Preeclampsia (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Medical College of Wisconsin
    New trial
    28d
    Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Medical College of Wisconsin
    New trial
    1m
    Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans (clinicaltrials.gov)
    P2, N=112, Active, not recruiting, University of Colorado, Boulder | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    1m
    Oxphos targeting of MYCN-amplified neuroblastoma. (PubMed, Front Oncol)
    The DPI and MitoQ combination further synergizes with vincristine, a chemotherapeutic agent used in NB treatment. Phosphoproteomics and proteomics analysis suggests that the drug combination induces MNA NB cell death by arresting the cell cycle and inhibiting oxidative phosphorylation (OXPHOS) in the mitochondria. Thus, interference with mitochondrial metabolism may represent an effective strategy to enhance the activity of chemotherapeutic drugs in MNA-NB.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN expression
    |
    vincristine